Clearside Biomedical Stock Quote CLSD - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

1.19

Bid

1.12

Ask

1.19

Volume

1,118,241

1.10 Day's Range 1.24

0.650101 52 Week Range 2.12

Market Cap

88.947M

Previous Close

1.24

Open

1.23

Last Trade

1.19

Last Trade Time

Financial Volume

$ 1,297,925

VWAP

1.1607

Average Volume (3m)

677,089

Shares Outstanding

74,745,572

Dividend Yield

PE Ratio

-2.72

Earnings Per Share (EPS)

-0.43

Revenue

8.23M

Net Profit

-32.49M

Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye. The product candidates of the company focus on a disease affecting the retina and aim to restore or improve visual functio... Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye. The product candidates of the company focus on a disease affecting the retina and aim to restore or improve visual function primarily by reducing the macular edema associated with several diseases affecting vision. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.clearsidebio.com

Headquarters

Wilmington, Delaware, USA

Founded

Clearside Biomedical Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CLSD. The last closing price for Clearside Biomedical was $1.24. Over the last year, Clearside Biomedical shares have traded in a share price range of $ 0.650101 to $ 2.12.

Clearside Biomedical currently has 74,745,572 shares outstanding. The market capitalization of Clearside Biomedical is $92.68 million. Clearside Biomedical has a price to earnings ratio (PE ratio) of -2.72.

Form 8-K - Current report

Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

- Maintained Stable Visual Acuity and Anatomical Control Over 9 Months - - Positive Safety Profile with No Ocular or Treatment-Related Serious Adverse Events - - 67% of CLS-AX Participants Did...

Clearside Biomedical’s Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of ARCATUS® for Suprachoroidal Use in Uveitic Macular Edema Patients in China

ALPHARETTA, Ga., July 29, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...

Form 8-K - Current report

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.29	-19.5945945946	1.48	1.65	1.16	4653651	1.32087207	CS
4	-0.09	-7.03125	1.28	1.65	1.09	1452708	1.31300549	CS
12	0	0	1.19	1.65	0.92	677089	1.25447787	CS
26	-0.08	-6.29921259843	1.27	1.65	0.92	418175	1.25997781	CS
52	0.308	34.9206349206	0.882	2.12	0.650101	348474	1.30898166	CS
156	-4.47	-78.9752650177	5.66	6.12	0.650101	330572	1.82004079	CS
260	0.4	50.6329113924	0.79	7.73	0.650101	563944	2.93591826	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
TVGNTevogen Bio Holdings Inc	$ 1.08 (184.51%)	249.54M
DRUGBright Minds Biosciences Inc	$ 2.49 (130.58%)	21.5M
INVOINVO BioScience Inc	$ 1.2246 (86.96%)	56.08M
VERBVerb Technology Company Inc	$ 12.80 (61.82%)	37.9M
RANIRani Therapeutics Holdings Inc	$ 3.18 (57.43%)	55.21M
MTEMMolecular Templates Inc	$ 0.39 (-73.47%)	7.22M
ZPTAZapata Computing Holdings Inc	$ 0.0768 (-70.57%)	44.51M
VEVVicinity Motor Corporation	$ 0.0735 (-37.23%)	8.44M
TWGTop Wealth Group Holding Ltd	$ 4.59 (-35.71%)	11.25M
VCIGVCI Global Ltd	$ 0.1034 (-23.97%)	14.46M
TVGNTevogen Bio Holdings Inc	$ 1.08 (184.51%)	249.54M
NVDANVIDIA Corporation	$ 138.07 (2.43%)	232.42M
GRTSGritstone bio Inc	$ 0.0544 (6.88%)	172.2M
SOFISoFi Technologies Inc	$ 10.04 (11.43%)	116.83M
SQQQProShares UltraPro Short QQQ	$ 6.99 (-2.51%)	113.93M